Why is Cldx going up?
Shares of Celldex Therapeutics (NASDAQ:CLDX), a clinical-stage biotechnology company, are rising in response to insider stock purchases and large equity stakes acquired by independent investment firms. A stock market encouraged by the signs of confidence has driven shares 29.2% higher as of 3:42 p.m. EDT on Friday.
Is Cldx a buy?
Celldex Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
What does Celldex Therapeutics do?
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
Do you know something about Celldex ( cldx ) stock?
Do Options Traders Know Something About Celldex (CLDX) Stock We Don’t? This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it?
What are Zacks experts saying Now about cldx?
CLDX: What are Zacks experts saying now? Do Options Traders Know Something About Celldex (CLDX) Stock We Don’t? This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it?
Is the options market predicting a spike in Celldex Therapeutics ( cldx ) stock?
What You Should Know Is the Options Market Predicting a Spike in Celldex Therapeutics (CLDX) Stock? Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
What is the stock price of Celldex Therapeutics?
In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 892,857 shares of common stock at the public offering price, less underwriting discounts and commissions. Jeffe What happened Shares of Celldex Therapeutics (NASDAQ: CLDX) were jumping 10.8% higher as of 3:10 p.m. EDT on Tuesday.